Prediction of the clinicopathological subtypes of breast cancer using a fisher discriminant analysis model based on radiomic features of diffusion-weighted MRI

Table 1 Clinicopathological Subtypes and Clinical Decision-Making [Ref [5]

Clinicopathological Subtype	IHC status	Clinical Decision-Making
Luminal A	ER and/or PR positive HER2 negative Ki-67 low (< 14%)	Endocrine therapy
^aLuminal B_HER2-	ER and/or PR positive HER2 negative Ki-67 high	Endocrine±cytotoxic therapy
^bLuminal B_HER2+	ER and/or PR positive any Ki-67 HER2 over-expressed	Cytotoxics + anti-HER2 + endocrine therapy
HER2 positive	HER2 over-expressed	Cytotoxics + anti-HER2
Triple negative	ER and PR absent HER2 negative	Cytotoxics

^aLuminal B_HER2- luminal B/HER2 negative, ^bLuminal B_HER2+ luminal B/HER2 positive, IHC immunohistochemistry

ISSN: 1471-2407